BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 7985257)

  • 1. [Long-term effect of 131I therapy of multinodular non-toxic goiter].
    Nygaard B; Hegedüs L; Gervil M; Jensen HH; Søe-Jensen P; Hansen JE
    Ugeskr Laeger; 1994 Sep; 156(39):5699-703. PubMed ID: 7985257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioiodine treatment of multinodular non-toxic goitre.
    Nygaard B; Hegedüs L; Gervil M; Hjalgrim H; Søe-Jensen P; Hansen JM
    BMJ; 1993 Oct; 307(6908):828-32. PubMed ID: 8401123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Can radioactive iodine be used in the treatment of diffuse non-toxic goiter?].
    Nygaard B; Hegedüs L; Bennedbaek FN; Veje A; Faber JO; Hansen JE
    Ugeskr Laeger; 1998 Sep; 160(37):5349-52. PubMed ID: 9748860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioiodine therapy in non-toxic multinodular goitre. The possibility of effect-amplification with recombinant human TSH (rhTSH).
    Bonnema SJ; Nielsen VE; Hegedüs L
    Acta Oncol; 2006; 45(8):1051-8. PubMed ID: 17118838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
    Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of hyperthyroidism caused by Graves' disease or toxic multinodular goitre by radioiodine: over 80% cure retrospectively after one calculated dose].
    Bakker SC; Zanin DE; Zweers EJ
    Ned Tijdschr Geneeskd; 2002 Sep; 146(39):1837-41. PubMed ID: 12382370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term results of two schedules of treatment for toxic multinodular goitre with radioiodine therapy.
    Khanna CM; Magdam M; Ravishankar L; Dham DN; Chugh P
    J Assoc Physicians India; 1995 Oct; 43(10):685-8. PubMed ID: 8773004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of long-term results of two schedules of treatment for toxic multinodular goitre with radioiodine therapy (I 131).
    Khanna CM; Magdum M; Ravishankar L; Dham DN; Chugh P
    J Assoc Physicians India; 1996 Feb; 44(2):102-5. PubMed ID: 10999060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
    Berg GE; Michanek AM; Holmberg EC; Fink M
    J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioiodine therapy for multinodular toxic goiter.
    Nygaard B; Hegedüs L; Ulriksen P; Nielsen KG; Hansen JM
    Arch Intern Med; 1999 Jun; 159(12):1364-8. PubMed ID: 10386513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy.
    Nygaard B; Faber J; Veje A; Hegedüs L; Hansen JM
    Thyroid; 1999 May; 9(5):477-81. PubMed ID: 10365679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
    Giovanella L; De Palma D; Ceriani L; Vanoli P; Garancini S; Tordiglione M; Tarolo GL
    Radiol Med; 2000 Dec; 100(6):480-3. PubMed ID: 11307510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment with (131)I of toxic multinodular goiter. Assessment of a fixed dose protocol].
    Abós MD; Banzo J; Razola P; García F; Prats E
    Rev Esp Med Nucl; 2000 Jun; 19(3):182-6. PubMed ID: 11062080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosimetry and risk estimates of radioiodine therapy for large, multinodular goiters.
    Huysmans DA; Buijs WC; van de Ven MT; van den Broek WJ; Kloppenborg PW; Hermus AR; Corstens FH
    J Nucl Med; 1996 Dec; 37(12):2072-9. PubMed ID: 8970537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of hypothyroidism during long-term follow-up of patients with toxic nodular goitre after radioiodine therapy.
    Kahraman D; Keller C; Schneider C; Eschner W; Sudbrock F; Schmidt M; Schicha H; Dietlein M; Kobe C
    Clin Endocrinol (Oxf); 2012 Feb; 76(2):297-303. PubMed ID: 21854403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioiodine therapy in patients with amiodarone-induced thyrotoxicosis (AIT).
    Czarnywojtek A; Czepczynski R; Ruchala M; Wasko R; Zgorzalewicz-Stachowiak M; Szczepanek E; Zamyslowska H; Bartkowiak Z; Florek E; Sowinski J
    Neuro Endocrinol Lett; 2009; 30(2):209-14. PubMed ID: 19675515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute changes in thyroid volume and function following 131I therapy of multinodular goitre.
    Nygaard B; Faber J; Hegedüs L
    Clin Endocrinol (Oxf); 1994 Dec; 41(6):715-8. PubMed ID: 7889605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study.
    Howarth D; Epstein M; Lan L; Tan P; Booker J
    Eur J Nucl Med; 2001 Oct; 28(10):1489-95. PubMed ID: 11685491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Standard dose 131I therapy for toxic multinodular goiter in an endemic goiter region.
    Gonçalves E; Castro JA; Gross JL
    Braz J Med Biol Res; 1986; 19(6):723-9. PubMed ID: 3651625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of longterm outcome of radioiodine therapy of sporadic non-toxic goitre.
    Le Moli R; Wesche MF; Tiel-Van Buul MM; Wiersinga WM
    Clin Endocrinol (Oxf); 1999 Jun; 50(6):783-9. PubMed ID: 10468951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.